Spravato® (Esketamine) & Ketamine - FDA-Approved Treatment

Breakthrough Treatment forTreatment-Resistant Depression

FDA-approved Spravato® (esketamine) nasal spray and ketamine infusion therapy offer rapid relief for depression that hasn't responded to traditional treatments. Fast-acting, effective, and administered under medical supervision.

Learn more in our Knowledge Hub: Spravato® & Ketamine resources.

FDA-Approved
Rapid Relief
Medical Supervision
Treatment-Resistant
Learn More

What Are Spravato® and Ketamine?

Spravato® (esketamine) and ketamine are breakthrough treatments for treatment-resistant depression. They work differently than traditional antidepressants, targeting the NMDA receptor system to provide rapid relief when other medications haven't been effective.

FDA-Approved Spravato®

Esketamine nasal spray is FDA-approved for treatment-resistant depression, offering rapid relief when other treatments haven't worked.

FDA-Approved 2019

Ketamine Infusion Therapy

IV ketamine therapy provides fast-acting relief for severe depression, with effects often felt within hours of treatment.

Rapid Onset

Medical Supervision

All treatments are administered in our clinic under close medical supervision to ensure safety and optimal outcomes.

Safe & Monitored

Quick Treatment Sessions

Spravato® sessions last about 2 hours including monitoring. Ketamine infusions typically take 40-60 minutes.

2-Hour Sessions

Proven Effectiveness

Studies show significant improvement in treatment-resistant depression, with many patients experiencing relief within days.

70%+ Response Rate

Rapid Relief

Unlike traditional antidepressants that take weeks, Spravato® and ketamine can provide relief within hours to days.

Fast-Acting

Conditions We Treat

Spravato® and ketamine are FDA-approved for treatment-resistant depression and are being studied for other mental health conditions with promising results.

Treatment-Resistant Depression
FDA Approved
Major Depressive Disorder
FDA Approved
Suicidal Ideation
FDA Approved
Bipolar Depression
Off-Label
Post-Traumatic Stress Disorder
Off-Label
Anxiety Disorders
Off-Label
Chronic Pain
Research
Obsessive-Compulsive Disorder
Research

Note: Spravato® (esketamine) is FDA-approved for treatment-resistant depression. Ketamine infusions are used off-label for depression and other conditions based on clinical research. All treatments require medical evaluation and supervision.

Treatment Process

Your Spravato®/Ketamine Treatment Journey

A structured, medically supervised path from consultation to lasting relief—designed with your safety and success in mind

7
Steps
4-8
Weeks
2-8
Sessions
70%+
Response Rate
01

Free Consultation

15-20 minutes
02

Medical Evaluation

45-60 minutes
03

Insurance & Authorization

1-2 weeks
04

Treatment Sessions

2 hours (Spravato®) / 1 hour (Ketamine)
05

Post-Treatment Monitoring

2 hours post-treatment
06

Progress Assessment

Weekly
07

Maintenance & Follow-Up

Ongoing
Step 1 of 7

Free Consultation

FREE

Meet with our medical team to discuss your symptoms, treatment history, and determine if Spravato® or ketamine therapy is right for you.

Duration: 15-20 minutes

Important Safety Information

Driving Restriction: You cannot drive or operate machinery for the rest of the day after treatment. Arrange for transportation home.

Medical Supervision: All treatments are administered in our clinic under close medical supervision. You'll be monitored for 2 hours after Spravato® treatment.

Side Effects: Common side effects may include dissociation, dizziness, nausea, and sedation. These typically resolve within hours. Serious side effects are rare but will be monitored.

*Individual results may vary. Treatment outcomes depend on various factors including condition severity, treatment adherence, and individual response. Response rates represent clinical trial and real-world data averages.

Frequently Asked Questions

Your Spravato®/Ketamine Questions Answered

Get answers to the most common questions about Spravato® and ketamine treatment, safety, effectiveness, and what to expect during your journey to better mental health.

Spravato® (esketamine) is the S-enantiomer of ketamine, FDA-approved as a nasal spray for treatment-resistant depression. It's a more refined form of ketamine with FDA approval and specific dosing protocols. Ketamine infusions use the racemic mixture and are administered off-label for depression. Both work on the NMDA receptor system but have different administration methods and regulatory statuses.

Still Have Questions?

Our experienced medical team is here to help you understand Spravato® and ketamine treatment and determine if it's right for you. Contact us for a personalized consultation.

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with our medical team for personalized treatment recommendations. Spravato® is a registered trademark of Janssen Pharmaceuticals.

Still Have Questions?

Our experienced medical team is here to help you understand Deep TMS™ treatment and determine if it's right for you. Contact us for a personalized consultation.

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with our medical team for personalized treatment recommendations.